Indication: Hematological Malignancies
A Phase 1 Study of TG-1501 in Subjects with Relapsed or Refractory Lymphoma
Sub-indication: Hematological Malignancies
Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: TG Therapeutics, Inc
Learn more at ClinicalTrials.gov
Email for more information: Heme-NCIResearch@nortonhealthcare.org
